ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS

BACKGROUND: H3 K27M-mutant gliomas have a dismal clinical prognosis and no proven curative therapy. We report the updated clinical experience with ONC201, the first cancer-specific DRD2 antagonist, in adult and pediatric H3 K27M-mutant gliomas. METHODS: As of May 28, 2018, 26 patients with H3 K27M-m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Chi, Andrew, Arrillaga-Romany, Isabel, Gardner, Sharon, Wen, Patrick, Batchelor, Tracy, Hall, Matthew, Odia, Yazmin, Khatua, Soumen, Zaky, Wafik, McGovern, Susan, Harrison, Rebecca, de Groot, John, Sumrall, Ashley, Shonka, Nicole, Khatib, Zaid, Karajannis, Matthias, Mueller, Sabine, Tarapore, Rohinton, Merdinger, Krystal, Schalop, Lee, Allen, Joshua, Oster, Wolfgang, P Mehta, Minesh
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216189/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.067
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados